Conventional wearable cardioverter defibrillators (WCDs) analyze patient signals to determine if the patient is experiencing a cardiac arrest. If a ventricular tachycardia/ventricular fibrillation (VT/VF) arrest is suspected, the WCD will alarm to warn the patient and bystanders of an impending shock. Conventional WCDs often alarm inappropriately, for example when the patient is not in cardiac arrest. It has been found that the only commercially available WCD with published clinical performance gives an inappropriate or false shock alarm about once every three patient-days on average. These inappropriate or false alarms can be distressing for the patient and could lead to an unnecessary shock if the patient does not take action to intervene before the shock is applied. If the false alarm rate is too high, then the patient is likely to discontinue wearing the WCD.
Claimed subject matter is particularly pointed out and distinctly claimed in the concluding portion of the specification. However, such subject matter may be understood by reference to the following detailed description when read with the accompanying drawings in which:
It will be appreciated that for simplicity and/or clarity of illustration, elements illustrated in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, if considered appropriate, reference numerals have been repeated among the figures to indicate corresponding and/or analogous elements.
In the following detailed description, numerous specific details are set forth to provide a thorough understanding of claimed subject matter. It will, however, be understood by those skilled in the art that claimed subject matter may be practiced without these specific details. In other instances, well-known methods, procedures, components and/or circuits have not been described in detail.
In the following description and/or claims, the terms coupled and/or connected, along with their derivatives, may be used. In particular embodiments, connected may be used to indicate that two or more elements are in direct physical and/or electrical contact with each other. Coupled may mean that two or more elements are in direct physical and/or electrical contact. However, coupled may also mean that two or more elements may not be in direct contact with each other, but yet may still cooperate and/or interact with each other. For example, “coupled” may mean that two or more elements do not contact each other but are indirectly joined together via another element or intermediate elements. Finally, the terms “on,” “overlying,” and “over” may be used in the following description and claims. “On,” “overlying,” and “over” may be used to indicate that two or more elements are in direct physical contact with each other. It should be noted, however, that “over” may also mean that two or more elements are not in direct contact with each other. For example, “over” may mean that one element is above another element but not contact each other and may have another element or elements in between the two elements. Furthermore, the term “and/or” may mean “and”, it may mean “or”, it may mean “exclusive-or”, it may mean “one”, it may mean “some, but not all”, it may mean “neither”, and/or it may mean “both”, although the scope of claimed subject matter is not limited in this respect. In the following description and/or claims, the terms “comprise” and “include,” along with their derivatives, may be used and are intended as synonyms for each other.
Referring now to
A WCD 100 according to embodiments can be configured to defibrillate the patient 110 who is wearing and/or carrying the designated parts of the WCD 100. Defibrillating can be by the WCD 100 delivering an electrical charge to the patient's body in the form of an electric shock. The electric shock can be delivered in one or more pulses.
In particular,
Support structure 112 can be implemented in many different ways. For example, it can be implemented in a single component or a combination of multiple components. In embodiments, support structure 112 could include a vest, a half-vest, a garment, etc. In such embodiments such items can be worn similarly to analogous articles of clothing. In embodiments, support structure 112 could include a harness, one or more belts or straps, etc. In such embodiments, such items can be worn by the patient 110 around the torso, hips, over the shoulder, etc. In embodiments, support structure 112 can include a container or housing, which even can be waterproof. In such embodiments, the support structure 112 can be worn by being attached to the patient's body by adhesive material, for example as shown and described in U.S. Pat. No. 8,024,037 which is incorporated herein by reference in its entirety. Support structure 112 can even be implemented as described for the support structure of US Pat. App. No. US2017/0056682 which is incorporated herein by reference in its entirety. In such embodiments, the person skilled in the art will recognize that additional components of the WCD 100 can be in the housing of a support structure 112 instead of being attached externally to the support structure 112, for example as described in the US2017/0056682 document. There can be other examples.
When defibrillation electrodes 104 and 108 make good electrical contact with the body of patient 110, monitor 116 can administer, via electrodes 104 and 108, a brief, strong electric pulse through the body of the patient 110. Such a pulse is also known as shock, defibrillation shock, therapy, electrotherapy, therapy shock, etc. The pulse is intended to go through and restart the heart of the patient 110 in an effort to save the life of the patient 110. The pulse further can include one or more pacing pulses of lesser magnitude to simply pace the patient's heart if needed, and so on.
Some prior defibrillators may decide whether to defibrillate or not based on an electrocardiogram (ECG) signal of the patient 110. Monitor 116, however, may initiate defibrillation or hold-off defibrillation based on a variety of inputs with the ECG signal merely being one of these inputs, and the scope of the disclosed subject matter is not limited in this respect.
The WCD 100 according to embodiments can obtain data from patient 110. For collecting such data, the WCD 100 optionally may include an outside monitoring device (not shown) external to monitor 116. Such a device may be called an “outside” device because it could be provided as a standalone device, for example not within the housing of monitor 116. An outside monitoring device can be configured to sense or monitor at least one local parameter. A local parameter can be a parameter of patient 110, a parameter of the WCD 100, or a parameter of the environment, as will be described later in this document.
For some of these parameters, an outside monitoring device may include one or more sensors or transducers. Each one of such sensors can be configured to sense a parameter of patient 110, and to render an input responsive to the sensed parameter. In some embodiments the input is quantitative, such as values of a sensed parameter. In other embodiments the input is qualitative, such as informing whether or not a threshold is crossed, and so on. Sometimes these inputs about patient 110 are also called physiological inputs and patient inputs. In embodiments, a sensor can be construed more broadly, as encompassing many individual sensors.
Optionally, an outside monitoring device can be physically coupled to support structure 112. In addition, an outside monitoring device may be communicatively coupled with other components that are coupled to support structure 112. Such communication can be implemented by a communication module, as will be deemed applicable by a person skilled in the art in view of this description.
In some embodiments, one or more of the components of the shown WCD 100 may be customized for patient 110. This customization may include a number of aspects. For instance, support structure 112 can be fitted to the body of patient 110. For another instance, baseline physiological parameters of patient 110 can be measured, such as the heart rate of patient 110 while resting, while walking, motion detector outputs while walking, etc. The measured values of such baseline physiological parameters can be used to customize the WCD 100 in order to make its diagnoses more accurate, since patients' bodies differ from one another. Of course, such parameter values can be stored in a memory of the WCD 100, and so on. Moreover, a programming interface can be made according to embodiments, which receives such measured values of baseline physiological parameters. Such a programming interface may input automatically in the WCD 100 these, along with other data.
In one or more embodiments, for example as shown in
An alert button 120 can connect to hub 114 and may include a speaker and vibrator. In addition, alert button 120 can include a button to allow the patient 110 to divert or abort a defibrillator shock in the event the patient 110 believes an impending shock to be unnecessary. Alert button 120 can also be referred to as a stop button, a divert button, or a user interface, and the scope of the disclosed subject matter is not limited in this respect. Hub 114 can connect the electrodes of support structure 112 and the alert button 120 to monitor 116 which houses the main electronics and other components of WCD 100, which may be contained within a carry pack assembly 118 that may be carried by the patient 110 or worn on the patient's hip. Monitor 116 may include the battery 142, the defibrillator capacitor 136, user interface 140, and main processor 138 of WCD 100.
In some embodiments, the processor 138 is a TORPEDO System on Module (SOM) available from Logic PD, Inc. of Eden Prairie, Minnesota, USA, although the scope of the disclosed subject matter is not limited in this respect. Processor 138 is used to run some portions of the shock decision algorithm to determine when WCD 100 should apply a shock to the patient 110 and is capable of applying filters on four channels simultaneously while also controlling wireless communications and other functions of WCD 100. In some embodiments, at least some portions of the shock algorithm may be run by a controller or processor 410 located in the hub 114 as shown in and described with respect to
Referring now to
Referring now to
The ECG electrodes can comprise structures 220 integrated into the garment so as to be firmly retained. Wiring from the electrodes 220 to a hub connector 222 can be internal to the garment, for example disposed between the layers of the garment.
Referring now to
In embodiments, the ECG electrodes 220 are “dry” electrodes in that they are placed in direct contact against the skin with no gel or electrolyte on the surface of the electrode disk 310 or the patient's skin. The solid metal face of the electrode disk 310 is non-breathable and traps moisture against the skin. In some embodiments such moisture can enhance pickup of the ECG signal.
It should be noted that a capacitive electrode system may be able to pick up an ECG signal without moisture at the electrode-skin interface. Such capacitive electrodes, however, may be more subject to noise pickup because any motion that modulates the electrode-skin capacitance is readily converted to ECG artifacts that can alter the ECG signal and interfere with ECG analysis. The resistive property of the ECG electrode 220 is less susceptible to such ECG artifacts to help reduce the likelihood of a false or unnecessary shock event. Furthermore, although adhesive electrodes may contain an electrolyte that facilitates ECG signal pickup, adhesive electrodes need to be replaced periodically, and the electrolyte may dry out over time and become more susceptible to interfering with proper ECG analysis.
Referring now to
Isolation barrier 134 serves to isolate the preamplifier from processor 410 and the rest of the WCD 100 system. Signals from the ECG electrodes are provided to the preamplifier 132 which converts the ECG signals into digital signals using analog-to-digital converters (ADCs) 144. The digital signals are passed from the preamplifier 132 through the isolation barrier 134 to processor 410 through digital isolator 412. The processor 410 has a Universal Serial Bus (USB) interface that goes to the monitor 116 and the rest of the WCD 100 system. The isolation barrier 134 can also include a power isolator 416 to isolate the power provided to the preamplifier 132 from the power provided to the processor 410.
In some embodiments, ECG front end circuitry 400 includes an isolation barrier configured to electrically isolate preamplifier 132 from the main circuit ground to which other circuits of WCD 100 are connected, for example the circuitry of monitor 116. Isolation barrier 134 may in turn include an additional circuit ground isolated from the main circuit ground. This isolation enhances the quality of the acquired ECG data, which may result in fewer false alarms and increased patient safety. Non-isolated ECG acquisition systems are susceptible to environmental noise sources such as 60 Hz fields in the vicinity of the WCD 100. Patient leakage currents could be difficult to control. Further, electrical noise generated by switch mode power supplies or high voltage charging circuits could couple into the ECG acquisition system of the WCD 100. Thus, preamplifier 132 may have its own ground reference which is different from and isolated from the ground reference used by processor 410 and the remaining circuits of the WCD 100 including the circuits of monitor 116.
In one or more embodiments, isolation barrier 134 can include digital isolator 412 and power isolator 416. Digital isolator 412 can comprise any one or more types of isolators such as galvanic couplers, such as provided by inductance or capacitance devices, such as an isolation transformer or an isolation capacitor, or by a non-electrical means, such as an opto-isolator comprising for example photodiodes and/or phototransistors, and the scope of the disclosed subject matter is not limited in this respect. In some embodiments, the isolation barrier 134 provides protection from the voltages applied by the defibrillator discharge circuit provided by monitor 116. Power isolator 416 can be configured to transfer power across the isolation barrier 134 without providing DC coupling across the isolation barrier 134, for example using a transformer, although the scope of the disclosed subject matter is not limited in this respect.
In one or more embodiments, the preamplifier 132 has four single-ended ECG inputs receiving the ECG signals, an active right-leg drive, a wide dynamic range, and direct-current (DC) leads-off detection. In some embodiments, preamplifier 132 supports DC leads-off detection, and in other embodiments preamplifier supports alternating-current (AC) leads-off detection, or both, and the scope of the disclosed subject matter is not limited in this respect. In some embodiments, preamplifier 132 includes circuitry to measure the patient impedance values between the ECG electrodes. These impedance values can be used to detect the patient's respiration, for example as shown in U.S. application Ser. No. 15/792,860 filed Oct. 25, 2017, published as US 2018/0117299 A1, and which is incorporated herein by reference in its entirety. As shown in
In one or more embodiments, the isolation barrier 134 shown in
In some embodiments, the preamplifier 132 has a very high sample rate so the anti-aliasing filters have little impact on the ECG signal quality. The preamplifier 132 is to provide data to the processor 410 at a 2 kHz rate with a bandwidth from DC to 250 Hz. The software down samples to 500 Hz and further bandlimits the signal for algorithm processing. It should be noted that aspects of embodiments of the ECG front end circuitry 400 are disclosed in U.S. application Ser. No. 15/365,801 filed Nov. 30, 2016 which is incorporated herein by reference in its entirety
Referring now to
In one or more embodiments, the signals from four ECG electrodes can be combined to form six different vectors. In some embodiments, WCD 100 uses four vectors for QRS complex analysis and/or heart rate analysis to determine if a shock should be applied. The WCD 100 is also capable of performing the analysis and shock application determination if one or more of the vectors is noisy or one or more of the ECG leads is in a lead-off condition wherein the lead is not contacting the patient's skin or is not sufficiently contacting the patient's skin to allow an ECG signal to be obtained with that ECG lead. In some embodiments, three ECG electrodes may be used and three ECG vectors may be analyzed. In other embodiments, five or six ECG vectors may be analyzed using four ECG electrodes. In some embodiments, a single vector is used and analyzed. It should be noted that in general WCD 100 may use and analyze fewer than four vectors or greater than four vectors, and the number of vectors can be increased beyond six vectors by using additional ECG electrodes, and the scope of the disclosed subject matter is not limited in this respect.
In one or more embodiments as shown in
Referring now to
The WCD 100 monitors and analyzes ECG data 610 to make a shock/no-shock decision. A gatekeeper function 612 may be used to provide an early indication that an arrhythmia may be present in the patient 110. An example embodiment of this gatekeeper functionality is disclosed in U.S. application Ser. No. 15/715,500 filed Sep. 26, 2017 which is incorporated herein by reference in its entirety. In some embodiments, if an arrhythmia is suspected with the gatekeeper function 612, then the main rhythm analysis algorithm 614 is triggered to start analyzing successive segments 618 of ECG data, and a shock/no-shock decision is made for each of the individual segments 618. If a string of the segments 618, for example six segments, provide a shock decision, then an episode is opened (Open Episode) 620 in a state machine 616. In some embodiments, this starts an internal storage of ECG information in a memory of the WCD 100 for later review. After the Open Episode 620, if the shockable rhythm persists for a confirmation period, for example for two or more segments for ventricular fibrillation (VF) or nineteen or more segments for ventricular tachycardia (VT) in some embodiments, then the patient alert sequence (Alert Patient) 624 is initiated. If the patient 110 does not respond within a specified amount of time after initiation of the patient alert sequence, for example after 20 seconds, then a shock (Shock) 626 is delivered to the patient 110.
Referring now to
Referring now to
Example methods to measure QRS width are described in U.S. Pat. No. 9,592,403 which is incorporated herein by reference in its entirety.
Referring now to
If noise is present on the signal, WCD 100 can use the VT confirmation time for both VT and VF rhythm types. In some embodiments, methods of detecting noise in an ECG signal can be as disclosed in U.S. Pat. No. 9,757,581 which is incorporated herein by reference in its entirety. In some embodiments, a slow alarm pathway when ECG noise is detected can be as disclosed in U.S. Patent Application No. 62/538,159 filed Jul. 28, 2017 which is incorporated herein by reference in its entirety.
Referring now to
In some embodiments, the ECG data that is fed to the QRS detector in processor 138 is also filtered with a matched filter. Since the QRS waveform has a known shape, the matched filter can be used to identify the QRS waveform in the incoming ECG data. Embodiments of such a matched filter can be as described in U.S. patent application Ser. No. 15/724,317 filed Oct. 4, 2017 which is incorporated herein by reference in its entirety.
In some embodiments, a wearable cardioverter defibrillator, WCD 100, includes electrodes that render an ECG signal of the patient 110, and a processor 138 that receives ECG data are derived from the rendered ECG signal. The processor 138 may filter the received ECG data with a matched filter or a matched difference filter to detect QRS complexes and can compute a heart rate from the detected QRS complexes. The matched filter or matched difference filter itself can have coefficient values associated with a baseline QRS complex, which enhances detection.
Processor 138 renders the ECG signal internally and can include an optional initial filter. If provided, the initial filter may perform one or more types of filtering to the rendered ECG signal, such as passband filtering between 2.75 Hz to 25 Hz to remove artifacts at different frequencies, etc. The initial filter can be implemented by a conventional Finite Impulse Response (FIR) filter. In other embodiments, the initial filter can be provided within processor 138, operating digitally. In some embodiments, QRS complexes may be detected from outputs of the filters, and a heart rate (HR) can be computed from the detection results.
Referring now to
The processor 138 processes the digital ECG/QRS data received from the preamplifier 132 with one or more digital filters 1112. Since the preamplifier 132 has a wide dynamic range that is much wider than the amplitude range of the ECG signals, digital filters 1112 may be utilized to process the ECG/QRS data without concern for clipping the incoming signals. One of the digital filters 1112 may include a matched filter to facilitate identification of QRS pulses in the incoming data stream. The wide dynamic range of the preamplifier 132 allows at least most of the ECG filtering to happen in software without the signal being clipped. Digital filters 1112 can be very effective at removing artifacts from the ECG/QRS data and may contribute to the enhanced false positive performance, that is a lower false positive rate, of the WCD 100 according to embodiments as described herein.
The processor 138 can apply the rhythm analysis algorithm (RAA) 1114 using QRS width information and heart rate data extracted from the digital ECG data using the segment-based processing analysis 600 of
In one or more embodiments of the WCD 100, the digital filters 1112 coupled with the wide dynamic range of the preamplifier 132 of the ECG front end circuitry 400 may allow analysis of signals that otherwise would be clipped in systems with a more limited dynamic range. In addition, the matched filter of the digital filters 1112 preferentially highlights complexes similar to the patient's normal rhythm. As a result, artifacts that otherwise may be difficult to discriminate using other methods may be significantly attenuated by the matched filter to result in a lower false alarm rate of the WCD 100.
An example for computing outputs for a filter may be as follows, for example for a matched filter.
Output(n)=Σm=0length(f)f(m)*g(m−n)
The above equation is similar to one for convolution, and in particular discrete convolution. The convolution of two finite sequences is defined by extending the sequences to finitely supported functions on the set of integers. In the above equation, f(m) are the data values of the ECG signal. While filter equation is similar to convolution, it is not identical to it. Indeed, while convolution uses the indexes g(n−m), a matched filter uses them in reverse order, which is also time order g(m−n). Moreover, for the matched filter in the filter equation, go are the coefficient values that define the kernel, and are chosen from a representation of the QRS signal that is to be detected. In other words, for a QRS detector the plot of the matched filter coefficients would look like a QRS complex. Rather than being frequency selective, a matched filter is sensitive to a specific shape.
Matched filtering according to embodiments enhances ECG detection, for example by detecting a higher number of the QRS complexes. Matched filters for detecting QRS complexes are suitable for WCD 100. Most ECG monitors use adhesive electrodes, and if the ECG signal is too noisy, then better skin preparation is likely the best remedy. On the contrary, with the WCD 100 described herein, extreme noise can be tolerated even with using “dry” electrodes, which potentially can be very noisy. Patient motion can cause problems when the “dry” electrodes move relative to the patient's skin which can cause a motion artifact in the ECG. Thus, using matched filtering techniques, operation of the WCD 100 would not stop notwithstanding any and all artifacts. Additionally, a matched filter can be suitable for segment-based ECG processing as shown in and described with respect to
It is noted that the features of WCD 100 described above may contribute to a lower false alarm rate, thereby reducing the number of times that WCD 100 provides an alarm to the patient 110 alerting of a shock about to be applied that is unnecessary. For example, in one or more embodiments any one or more of the features of WCD 100 may contribute to WCD 100 having an average false alarm rate of less than one false alarm event every ten patient-days. Any one or more of the features of WCD 100 also may contribute to WCD 100 being required to store data from patient episodes an average of less than one every ten patient-days, thereby reducing the amount of storage need for the data and requiring less analysis of the patient episode data by medical professionals. In addition, any one or more of the features of WCD 100 also may contribute to WCD 100 requiring fewer patient interactions, for example requiring the patient 110 to intervene and stop a false alarm event using alert button 120.
In addition to the above described features of WCD 100, in accordance with one or more embodiments, any one or more of the following features of WCD 100 described below also can contribute to a lower false alarm rate. In one or more embodiments, the rhythm analysis algorithm utilized by WCD 100 measures the heart rate and QRS width for all channels, for example four channels in some embodiments, excluding those with obvious noise. In some embodiments, the QRS width is simply taken from the channel that gives the widest measured width and applied to the rhythm analysis algorithm as described with respect to
In some embodiments, the heart rate channel selection is a multi-step process. For example, embodiments of the overall channel selection process are described in U.S. Application No. 62/630,398 which is incorporated herein by reference in its entirety. As described for embodiments of the 62/630,398 application, an early operation is to estimate the heart rate error using the heart rate “Agreement” and QRS “Organization.” The Agreement is an assessment of whether an individual channel is consistent with other channels. The QRS Organization is a measure of whether the morphology of the complexes is similar throughout the segment 618. Segments 618 with a high Agreement and Organization are judged to have less heart rate error. As described for embodiments of the 62/630,398 application, in another operation, if the heart rate error is estimated to be too high, then the R-R intervals between QRS complexes 800 are “pooled” and the mode, the most common, R-R interval is used for determining the heart rate. For example, it is possible that the chosen heart rate does not correspond with the heart rate calculated for any given channel, which may raise questions. The processor may detect sequential peaks within the ECG signal, measure durations of time intervals between the peaks, including between non-sequential peaks, and identify a representative duration. The representative duration is the one that occurs the most often, i.e., the mode. Then a heart rate can be computed from a duration indicated by the representative duration and, if the heart rate meets a shock condition, the WCD 100 may deliver a shock to the patient 110. The representative duration can be close to a good R-R interval measurement of a patient, notwithstanding any noise in the ECG signal. A WCD 100 incorporating this method may have logic for deciding when to use the heart rate mode or when to use a simpler method. The mode tends to be useful when there is a substantial disagreement in the heart rate between channels and there is not an obvious reason for disqualifying one or more channels such as a dislodged ECG lead. The pooling process is described in U.S. Application No. 62/501,009 filed May 3, 2017 and is child application Ser. No. 15/948,884 filed Apr. 9, 2018 which are incorporated herein by reference in their entireties.
Thus, in one or more embodiments WCD 100 is designed to select the ECG channel judged to have the least heart rate error regardless of noise. In such an approach, noise on the signal may or may not interfere with the heart rate measurement. It is noted that heart rate data may be less susceptible to noise than ECG data. As a result, using heart rate data as part of the RAA process to determine if a patient is experiencing a shockable cardiac event can mitigate and/or reduce the false alarm rate of the WCD 100.
In some embodiments, accelerometer-based motion analysis can preclude a shock decision while a patient is walking while wearing the WCD 100. The hub 114 may include accelerometer 414 to provide accelerometer information to an Accelerometer Algorithm (AA). In some embodiments, the accelerator algorithm may be implemented as disclosed in U.S. Patent Application No. 62/446,820 filed Jan. 16, 2017 which is incorporated herein by reference in its entirety. Embodiments of the AA will cause the Rhythm Analysis Algorithm (RAA) to not classify a segment 618 with a shock result if the AA judges that the patient 110 is walking.
Since walking is a common activity, walking is easy to detect using the AA. Detection of walking can provide a definitive indication that the patient 110 is not in cardiac arrest. Moreover, patient movement such as walking tends to create ECG artifacts that could confuse the RAA and cause a false shock alarm. When WCD 100 utilizes embodiments of the AA, the RAA will return a no-shock result while the patient 110 is walking thereby reducing or avoiding false alarms at a time when a typical WCD might otherwise be prone to false alarms.
In some embodiments, the AA can be configured to detect other types of patient motion in addition to walking. For example, a patient 110 in cardiac arrest will not be moving voluntarily but may exhibit reflexive skeletal muscle convulsions in which case the patient 110 may appear to gasp for breath in a manner known as agonal breathing. In addition, a patient 110 may experience cardiac arrest in a moving vehicle, and WCD 100 can be configured to not mistakenly inhibit therapy because of that motion.
In some embodiments, WCD 100 can be configured to detect other voluntary patient motion such as running, riding a bicycle, dancing, performing calisthenics, exercising on a stepper or elliptical machine, and so on, that would indicate that the patient 110 is not in cardiac arrest, while still rejecting movements that are consistent with a person in cardiac arrest such as reflexive skeletal muscle convulsion and agonal breathing described above. In such embodiments, WCD 100 can be configured to prevent false shock alarms for a wide range of patient activities in addition to walking.
In some embodiments, the WCD 100 is configured to have noise detection that is capable of distinguishing high-amplitude artifacts from QRS complexes 800. Example noise detection is disclosed in U.S. patent application Ser. No. 15/861,463 filed Jan. 3, 2018 which is incorporated herein by reference in its entirety. In embodiments as described in the Ser. No. 15/861,463 application, the WCD 100 can detect high amplitude noise such as QRS complexes or a baseline shift larger than a threshold such as 5 mV, and high frequency noise as a number of baseline crossings or number of extremely narrow ECG peaks greater than a threshold. When high-frequency noise is present on the signal and the patient 110 has an apparent shockable rhythm, in some embodiments the WCD 100 uses the VT pathway as described with respect to
In some embodiments, the WCD 100 is configured to utilize “Sticky” leads-off and noise processing detects periods of leads-off and noise and precludes rhythm analysis until the signals have cleared up. The WCD 100 can be configured to keep a circular buffer of noise analysis results, and if the number of the “Noisy” results exceed a threshold, then the WCD 100 enters a “Noise State”. For example, in some embodiments, if two out of the last five analysis results are Noisy, then the WCD 100 enters the Noise State. Further rhythm analysis is inhibited while the WCD 100 is in the Noise State. The WCD 100 stays in the Noise State until five successive segments 618 yield a non-noisy result.
In some embodiments, if one ECG lead is detected as being “off”, that is not touching the patient's skin, then the vectors derived from that electrode are excluded from further analysis. The WCD 100, however, continues to analyze the remaining vectors. Further, in some four-channel embodiments, if two ECG leads are detected as being “off” then the segment 618 is marked as Analysis Not Possible (ANP). If three out of five segments 618 are marked as ANP, then the WCD 100 enters the ANP state. Further rhythm analysis is suspended while the WCD 100 is in the ANP state. The WCD 100 stays in the ANP state until five successive segments 618 are detected not to be ANP.
Both the Noise State and the ANP state may be referred to as being “sticky” in some embodiments because once the WCD 100 enters either state, it is relatively difficult for WCD 100 to leave that state. This is so because ECG signals actually may be corrupted without tripping either the leads-off or the noise thresholds. If some segments 618 trip either a noise or leads-off threshold, it is likely that subsequent segments 618 may be corrupted even if the WCD 100 is unable to detect the corruption. To avoid this problem, in some embodiments the WCD 100 is configured to wait for a series of apparently clean segments before resuming analysis. Embodiments of this approach are described in more detail in U.S. Patent Application No. 62/538,145 filed on Jul. 28, 2017 which is incorporated herein by reference in its entirety.
In general, the wearable cardioverter defibrillator WCD 100 as disclosed herein is capable of operating with a reduced false alarm rate. Conventional WCDs analyze patient signals to determine if the patient is experiencing a cardiac arrest. If a VT/VF arrest is suspected, the WCD 100 will alarm to warn the patient and bystanders of an impending shock. Conventional WCDs often alarm inappropriately, that is when the patient is not in cardiac arrest. The Zoll LifeVest is the only WCD with published clinical performance. It has been discovered that the Zoll LifeVest WCD gives an inappropriate shock alarm about once every three patient-days on average. The Zoll Lifevest 4000 Operator's manual documents a WCD clinical study in which 13 patients wore WCDs for a collective total of 735 patient-days and experienced inappropriate shock alarms every 3.4 patient-days. These alarms can be distressing for the patient and, if the patient does not take action to intervene during a false alarm, an unnecessary shock could be applied. See for example, Olgin J E, Pletcher M J, Vittinghoff E, et al., “Wearable Cardioverter-Defibrillator after Myocardial Infarction,” N Engl J Med 2018 Sep. 27; 379(13):1205-1215.
Because WCD patients are conscious, ambulatory people who go about their daily lives, sensor signals may experience artifacts from patient motion or from the environment. It is believed that such artifacts may cause the conventional WCD to incorrectly judge the patient 110 to be in cardiac arrest and lead to inappropriate alarms. Occasionally, conventional WCDs may misinterpret the patient's ECG signal, mistaking a non-shockable rhythm for a shockable rhythm. A recent publication by Schuhmann et al., “Experience with the wearable cardioverter defibrillator (WCD) in high risk cardiac patients from a German single center cohort”, Heart Rhythm 2016; 13(5):5254 showed that 97% of WCD false alarms were due to noise or artifacts and only 3% were true ventricular arrhythmias.
A recent clinical study of WCD Performance for Clinical Review, Sullivan et al., “A Novel Wearable Cardioverter Defibrillator With Reduced False Alarm Rate,” AHA 2017 abstract, included 50 patients who wore embodiments of WCD 100 according to the present disclosure for a total of 82 patient-days. No false shock alarms were given during this study. Statistically, it can be stated with 95% confidence that WCD 100 gives inappropriate shock alarms less than once every 27 patient-days.
In some embodiments, in order to assess the effect of device-triggered episodes, the WCD 100 stores an episode such as a short clip or duration of the ECG data when the WCD 100 detects a potentially shockable rhythm. If the rhythm spontaneously converts, or if the algorithm changes its shock decision, or if the patient 110 presses the divert/alert/stop shock button, then the patient 110 does not receive a shock. Even though the patient 110 is not shocked, the episode is stored for analysis. Stored episodes can be of diagnostic value to clinicians.
In contrast, with the Zoll LifeVest, device-triggered episodes are likely of limited clinical value because they are almost always due to noise, not a true cardiac arrhythmia. Because of the low false alarm rate embodiments of the WCD 100 of the present disclosure, fewer episodes due to noise will need to be stored. The episodes that are stored are more likely to represent a cardiac event that is of clinical interest. In the Sullivan study cited above, only one patient generated any episodes due to noise, and that patient is one who would probably be contraindicated for a WCD because of the type of pacemaker that patient had. Accordingly, the low false alarm rate of WCD 100 may apply to cardiac patients with a low ejection fraction, for example less than about 40%, who are wearing the WCD 100 during normal daily activities, although the scope of the disclosed subject matter is not limited in this respect.
As discussed herein, WCD 100 has a low false alarm rate. Furthermore, WCD 100 also has a low false episode rate. When WCD 100 makes a determination that a patient 110 has an arrhythmia, WCD 100 opens an episode and begins to store data related to the episode. For example, processor 138 of monitor 116 stores the episode data in a non-volatile or flash memory such as an internal memory or in a removable memory card such as Secure Digital (SD) card and/or Multimedia Card (MMC) (SD/MMC) or similar. If the arrythmia persists, then the WCD 100 generates an alarm. If the patient does not respond to the alarm within a predetermined period of time to intervene and stop the impending shock, then the WCD 100 delivers a therapeutic shock to the patient 110. Episode data is stored so that a physician can review the episode data to analyze what the patient's heart rhythm looked like during the episode in order to understand what is wrong with the patient even when a shock is not delivered.
False episodes may be incurred due to noise or signal artifacts just like false alarms. False episodes can be annoying to the physician because there could be nothing wrong with the patient's heart even though an episode occurred. As a result, the physician may need to review a large number of false episodes in order to find one true episode from a set of episodes. Sifting through such a large number of false episodes, however, may be a tedious and inefficient task for the physician, and as a result the physician may be disinclined to review the stored episodes at all if the vast majority of them are merely due to noise and not any issue with the patient's heart. Thus, providing a WCD 100 with a low false episode rate can facilitate physician review of the patient's episode data.
In accordance with one or more embodiments, the same mechanisms discussed herein that contribute to WCD 100 having a low false alarm rate also contribute to WCD 100 having a low false episode rate. Additionally, unnecessary shocks also can be problematic. A WCD that is confused by noise on the ECG would also be more prone to giving unnecessary shocks. Unnecessary shocks can be very traumatic for the patient 110 because the shocks can be painful, and it is possible that an unnecessary shock could trigger the patient 110 into a life-threatening arrhythmia. In accordance with one or more embodiments, the same mechanisms discussed herein that contribute to WCD 100 having a low false alarm rate also contribute to WCD 100 having a low unnecessary or false shock rate.
It should be noted that although this disclosure describes various embodiments, after careful review of this disclosure one skilled in the art will recognize that other embodiments also can yield a low false alarm rate. For example, some of the described embodiments employ a garment or support structure 112 that holds the ECG electrodes in proximity to the patient's skin. In other embodiments, techniques described in this disclosure could be implemented in devices that adhesively attach to the patient's skin or use a combination of adhesive pieces and removable pieces. In other embodiments, a low false alarm rate can be achieved by incorporating additional patient monitoring parameters. For example, ECG analysis can be coupled with a pulse detection circuit to confirm cardiac arrest before alarming the patient 110.
The following examples may be implemented in accordance with one or more embodiments. In example one, a wearable cardioverter defibrillator (WCD) comprises a plurality of electrocardiography (ECG) electrodes, a right-leg drive (RLD) electrode, and a plurality of defibrillator electrodes to contact the patient's skin when the WCD is delivering therapy to the patient, a user interface, a preamplifier coupled to the ECG electrodes and the RLD electrode to obtain ECG data from the patient as one or more ECG vectors, a processor to receive ECG data from the preamplifier and an abort signal from the user interface, an isolation barrier to isolate the preamplifier from the processor, and a high voltage subsystem to provide a defibrillation voltage to the patient through the plurality of defibrillator electrodes in response to a shock signal received from the processor. The processor is to determine when a shock criterion is met based on the ECG data from the preamplifier, and to provide the shock signal in the event the shock criterion is met and the abort signal is not received within a predetermined time period of the shock criterion being met. In example two, the processor is to determine QRS width data and heart rate data from the ECG data, and to determine when the shock criterion is met based on the QRS width data and the heart rate data. In example three, the preamplifier includes one or more analog-to-digital converters (ADCs) to convert the ECG data into digitized ECG data that is provided across the isolation barrier to the processor. In example four, the one or more vectors comprises four vectors. In example five, the processor is to monitor the one or more ECG vectors, and is configured to determine when the shock criterion is met when one or more of the ECG vectors is noisy or when one or more of the plurality of ECG electrodes is in a lead-off condition. In example six, the preamplifier is configured to receive the ECG data as differential signals using a voltage of the RLD electrode as a common mode signal or a common mode potential. In example seven, the preamplifier has a dynamic range at an input that is an order of magnitude or greater than a magnitude of the ECG data. In example eight, the ECG data received by the processor from the preamplifier is processed using one or more digital filters. In example nine, one or more QRS pulses are identified in the ECG data using a matched filter in the processor to determine the QRS width data and/or the heart rate data. In example ten, one or more of the plurality of ECG electrodes comprises a dry electrode to directly contact the patient's skin without using a gel or an adhesive. In example eleven, one or more of the ECG electrodes comprises a silver disk or a silver plated copper disk. In example twelve, one or more of the ECG electrodes comprises a resistive electrode. In example thirteen, the processor is to process the ECG data received from the preamplifier in segments of ECG data, wherein the shock criterion is met when a string of a predetermined number of segments indicate a shock decision should be made. In example fourteen, the preamplifier is configured to obtain one or more impedance values between the ECG electrodes, and to provide digitized impedance values to the processor across the isolation barrier. In example fifteen, the processor incurs less than one false alarm indicating the shock criterion has been met every ten patient-days.
In example sixteen, a method to determine whether a defibrillation shock should be applied with a wearable cardioverter defibrillator (WCD) comprises receiving electrocardiography (ECG) data from a patient using the WCD with a preamplifier coupled to one or more ECG electrodes and a right-leg drive (RLD) electrode coupled to the patient's skin to obtain ECG data from the patient as one or more ECG vectors, receiving ECG data from the preamplifier with a processor through an isolation barrier to electrically isolate the preamplifier from the processor, determining with the processor if a shock criterion is met based on a combination of heart rate data and a width of one or more QRS pulses identified in the ECG data, signaling the patient that the defibrillation shock is about to be applied, and applying the defibrillation shock to the patient unless a stop shock signal is caused by the patient within a predetermined period of time after signaling the patient. In example seventeen, the method further comprises converting the ECG data into digitized ECG data and providing the digitized ECG data across the isolation barrier to the processor. In example eighteen, the one or more vectors comprises four vectors. In example nineteen, said determining when the shock criterion is met occurs even when one or more of the ECG vectors is noisy or when one or more of the ECG electrodes is in a lead-off condition. In example twenty, the method further comprises processing the ECG data with the processor using one or more digital filters. In example twenty-one, the method further comprises identifying the one or more QRS pulses in the ECG data using a matched filter in the processor. In example twenty-two, the method further comprises processing the ECG data with the processor in segments of ECG data, wherein the shock criterion is met when a string of a predetermined number of segments indicate a shock decision should be made. In example twenty-three, the method further comprises obtaining one or more impedance values between the ECG electrodes with the preamplifier, and providing digitized impedance values to the processor across the isolation barrier. In example twenty-four, the method further comprises incurring less than one false alarm indicating the shock criterion has been met every ten patient-days.
In example twenty-five, wearable cardioverter defibrillator (WCD) system comprises a support structure comprising a plurality of electrocardiography (ECG) electrodes, a right-leg drive (RLD) electrode, and a plurality of defibrillator electrodes to contact the patient's skin when the WCD is delivering therapy to the patient, a hub comprising a preamplifier coupled to the ECG electrodes and the RLD electrode to obtain ECG data from the patient as one or more ECG vectors, and an isolation barrier to electrically isolate the preamplifier, an alert button coupled to the hub, and a monitor coupled to the hub and comprising a processor to receive the ECG data from the preamplifier through the isolation barrier, and a high voltage subsystem to provide a defibrillation voltage to the patient through the plurality of defibrillator electrodes in response to a shock signal received from the processor in the event a shock criterion is met and a stop shock signal is not received from the patient via the alert button prior to application of the defibrillation signal within a predetermined period of time after the shock criterion is met. The processor is to determine if the shock criterion is met based on a combination of the heart rate data identified in the ECG data and a width of one or more QRS pulses identified in the ECG data. In example twenty-six, the preamplifier has a dynamic range at an input that is an order of magnitude or greater than a magnitude of the ECG data, wherein the dynamic range allows the ECG data received by the processor to be processed using one or more digital filters without clipping. In example twenty-seven, the one or more QRS pulses are identified in the ECG data using a matched filter in the processor. In example twenty-eight 28, the processor is to process the ECG data received from the preamplifier in periodic segments, wherein the shock criterion is evaluated for each of the segments of ECG data, and a shock decision is made when the shock criterion is met for a predetermined number of successive segments. In example twenty-nine, the processor incurs less than one false alarm indicating the shock criterion has been met every ten patient-days.
In example thirty, a wearable cardioverter defibrillator (WCD) comprises a plurality of electrocardiography (ECG) electrodes and a plurality of therapy electrodes, the plurality of ECG electrodes and the plurality of therapy electrodes arranged to operatively contact a patient's skin when the WCD is operably attached to the patient, an amplifier coupled to the plurality of ECG electrodes to obtain multi-vector ECG data from the patient, an energy storage device configured to store an electrical charge, a high voltage subsystem coupled to the energy storage device and the plurality of therapy electrodes, and a processor coupled to the amplifier, the high voltage subsystem, and a user interface. The processor is configured to issue an alarm if a shock criterion is met, wherein the alarm is issued with a false alarm rate of less than one false alarm in ten patient days, and cause the high voltage subsystem to discharge the stored electrical charge from the energy storage device to the patient in response to the patient failing to respond to the alarm via the user interface within a predetermined time. In example thirty-one, the WCD further comprises a right-leg drive (RLD) electrode coupled to the amplifier to provide a common mode reference for the multi-vector ECG data. In example thirty-two, the WCD further comprises an isolation barrier to isolate the amplifier from the processor, wherein the amplifier is configured to transmit a digitized version of the multi-vector ECG data across the isolation barrier to the processor. In example thirty-three, at least one parameter of the multi-vector ECG data comprises heart rate, QRS width, QRS organization, or accelerometer data, or a combination thereof. In example thirty-four, the processor is configured to determine QRS width, heart rate, or QRS organization, or a combination thereof, from the multi-vector ECG data.
Other embodiments include combinations and sub-combinations of features described or shown in the drawings herein, including for example, embodiments that are equivalent to: providing or applying a feature in a different order than in a described embodiment, extracting an individual feature from one embodiment and inserting such feature into another embodiment, removing one or more features from an embodiment, or both removing one or more features from an embodiment and adding one or more features extracted from one or more other embodiments, while providing the advantages of the features incorporated in such combinations and sub-combinations. As used in this paragraph, feature or features can refer to the structures and/or functions of an apparatus, article of manufacture or system, and/or the operations, acts, or modalities of a method.
Although the claimed subject matter has been described with a certain degree of particularity, it should be recognized that elements thereof may be altered by persons skilled in the art without departing from the spirit and/or scope of claimed subject matter. It is believed that the subject matter pertaining to a wearable cardioverter defibrillator (WCD) with a low false alarm rate and many of its attendant utilities will be understood by the foregoing description, and it will be apparent that various changes may be made in the form, construction and/or arrangement of the components thereof without departing from the scope and/or spirit of the claimed subject matter or without sacrificing all of its material advantages, the form herein before described being merely an explanatory embodiment thereof, and/or further without providing substantial change thereto. It is the intention of the claims to encompass and/or include such changes.
The present application is a divisional of U.S. application Ser. No. 16/382,575 filed Apr. 12, 2019, now U.S. Pat. No. 11,160,990, which in turn claims the benefit of U.S. Provisional Application No. 62/630,695 filed Feb. 14, 2017. Said application Ser. No. 16/382,575 and said Application No. 62/630,695 are hereby incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3644925 | Kupsky et al. | Feb 1972 | A |
3724455 | Unger | Apr 1973 | A |
4291699 | Geddes et al. | Sep 1981 | A |
4583524 | Hutchins | Apr 1986 | A |
4617938 | Shimoni et al. | Oct 1986 | A |
4619265 | Morgan et al. | Oct 1986 | A |
4895151 | Grevis et al. | Jan 1990 | A |
4928690 | Heilman et al. | May 1990 | A |
4955381 | Way et al. | Sep 1990 | A |
5078134 | Heilman et al. | Jan 1992 | A |
5228449 | Christ et al. | Jul 1993 | A |
5348008 | Bornn et al. | Sep 1994 | A |
5353793 | Bornn | Oct 1994 | A |
RE34800 | Hutchins | Nov 1994 | E |
5376104 | Sakai | Dec 1994 | A |
5381803 | Terleikson et al. | Jan 1995 | A |
5394892 | Kenny et al. | Mar 1995 | A |
5405362 | Kramer et al. | Apr 1995 | A |
5425749 | Adams | Jun 1995 | A |
5474574 | Payne et al. | Dec 1995 | A |
5554174 | Causey, III | Sep 1996 | A |
5601612 | Gliner et al. | Feb 1997 | A |
5630834 | Bardy | May 1997 | A |
5662690 | Cole et al. | Sep 1997 | A |
5709215 | Perttu et al. | Jan 1998 | A |
5769872 | Lopin et al. | Jun 1998 | A |
5782878 | Morgan et al. | Jul 1998 | A |
5792204 | Snell | Aug 1998 | A |
5803927 | Cameron et al. | Sep 1998 | A |
5819007 | Elghazzawi | Oct 1998 | A |
5902249 | Lyster | May 1999 | A |
5913685 | Hutchins | Jun 1999 | A |
5944669 | Kaib | Aug 1999 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6065154 | Hulings et al. | May 2000 | A |
6068651 | Brandell | May 2000 | A |
6108197 | Janik | Aug 2000 | A |
6148233 | Owen et al. | Nov 2000 | A |
6201992 | Freeman | Mar 2001 | B1 |
6263238 | Brewer et al. | Jul 2001 | B1 |
6287328 | Snyder et al. | Sep 2001 | B1 |
6304780 | Owen et al. | Oct 2001 | B1 |
6319011 | Motti et al. | Nov 2001 | B1 |
6334070 | Nova et al. | Dec 2001 | B1 |
6351671 | Myklebust et al. | Feb 2002 | B1 |
6356785 | Snyder et al. | Mar 2002 | B1 |
6427083 | Owen et al. | Jul 2002 | B1 |
6437083 | Brack et al. | Aug 2002 | B1 |
6529875 | Nakajima et al. | Mar 2003 | B1 |
6546285 | Owen et al. | Apr 2003 | B1 |
6671545 | Fincke | Dec 2003 | B2 |
6681003 | Linder et al. | Jan 2004 | B2 |
6694187 | Freeman | Feb 2004 | B1 |
6762917 | Verbiest et al. | Jul 2004 | B1 |
6941168 | Girouard | Sep 2005 | B2 |
7065401 | Worden | Jun 2006 | B2 |
7149576 | Baura et al. | Dec 2006 | B1 |
7336994 | Hettrick et al. | Feb 2008 | B2 |
7379771 | Kovac et al. | May 2008 | B2 |
7460900 | Gill et al. | Dec 2008 | B1 |
7559902 | Ting et al. | Jul 2009 | B2 |
7865238 | Brink | Jan 2011 | B2 |
7870761 | Valentine et al. | Jan 2011 | B2 |
7894894 | Stadler et al. | Feb 2011 | B2 |
7974689 | Volpe et al. | Jul 2011 | B2 |
8024037 | Kumar | Sep 2011 | B2 |
8036746 | Sanders | Oct 2011 | B2 |
8135462 | Owen et al. | Mar 2012 | B2 |
8140154 | Donnelly et al. | Mar 2012 | B2 |
8369944 | Macho et al. | Feb 2013 | B2 |
8548557 | Garstka et al. | Oct 2013 | B2 |
8615295 | Savage et al. | Dec 2013 | B2 |
8825154 | Jorgenson et al. | Sep 2014 | B2 |
8838235 | Cowan et al. | Sep 2014 | B2 |
8897860 | Volpe et al. | Nov 2014 | B2 |
8904214 | Volpe et al. | Dec 2014 | B2 |
8965500 | Macho et al. | Feb 2015 | B2 |
8996101 | Zhang et al. | Mar 2015 | B2 |
9008801 | Kaib et al. | Apr 2015 | B2 |
9089685 | Sullivan et al. | Jul 2015 | B2 |
9131901 | Volpe et al. | Sep 2015 | B2 |
9132267 | Kaib | Sep 2015 | B2 |
9408548 | Volpe et al. | Aug 2016 | B2 |
9454219 | Volpe et al. | Sep 2016 | B2 |
9533165 | Gunderson | Jan 2017 | B1 |
9592403 | Sullivan | Mar 2017 | B2 |
9757579 | Foshee, Jr. | Sep 2017 | B2 |
9757581 | Sullivan et al. | Sep 2017 | B2 |
10016614 | Sullivan et al. | Jul 2018 | B2 |
10322291 | Medema et al. | Jun 2019 | B2 |
11077310 | Sullivan | Aug 2021 | B1 |
11103717 | Sullivan et al. | Aug 2021 | B2 |
11160990 | Sullivan et al. | Nov 2021 | B1 |
11331508 | Cowan et al. | May 2022 | B1 |
20110022105 | Owen et al. | Jan 2003 | A9 |
20030158593 | Heilman et al. | Aug 2003 | A1 |
20030187479 | Thong | Oct 2003 | A1 |
20040049117 | Ideker et al. | Mar 2004 | A1 |
20040220623 | Hess | Nov 2004 | A1 |
20040230105 | Geva et al. | Nov 2004 | A1 |
20050107833 | Freeman et al. | May 2005 | A1 |
20050107834 | Freeman et al. | May 2005 | A1 |
20050131476 | Kim et al. | Jun 2005 | A1 |
20060017575 | McAdams | Jan 2006 | A1 |
20060173364 | Clancy | Aug 2006 | A1 |
20070179539 | DeGroot et al. | Aug 2007 | A1 |
20070203418 | Starc | Aug 2007 | A1 |
20080033495 | Kumar | Feb 2008 | A1 |
20080208070 | Snyder et al. | Aug 2008 | A1 |
20080215103 | Powers et al. | Sep 2008 | A1 |
20080306560 | Macho et al. | Dec 2008 | A1 |
20080312708 | Snyder | Dec 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090005827 | Weintraub et al. | Jan 2009 | A1 |
20090018595 | Bharmi et al. | Jan 2009 | A1 |
20100007413 | Herleikson et al. | Jan 2010 | A1 |
20100114248 | Donofrio et al. | May 2010 | A1 |
20100298899 | Donnelly et al. | Nov 2010 | A1 |
20100331904 | Warren et al. | Dec 2010 | A1 |
20110288604 | Kaib et al. | Nov 2011 | A1 |
20110288605 | Kaib et al. | Nov 2011 | A1 |
20120022355 | Byrd et al. | Jan 2012 | A1 |
20120150008 | Lanar et al. | Jan 2012 | A1 |
20120059270 | Grunwald | Mar 2012 | A1 |
20120108911 | Drysdale | May 2012 | A1 |
20120112903 | Kaib et al. | May 2012 | A1 |
20120144551 | Guldalian | Jun 2012 | A1 |
20120158075 | Kaib et al. | Jun 2012 | A1 |
20120265265 | Razavi et al. | Oct 2012 | A1 |
20120277638 | Skelton et al. | Nov 2012 | A1 |
20120283794 | Kaib et al. | Nov 2012 | A1 |
20120293323 | Kaib et al. | Nov 2012 | A1 |
20120302860 | Volpe et al. | Nov 2012 | A1 |
20120310315 | Savage et al. | Dec 2012 | A1 |
20120316611 | Armoundas et al. | Dec 2012 | A1 |
20130085538 | Volpe et al. | Apr 2013 | A1 |
20130231711 | Kaib | Sep 2013 | A1 |
20130245388 | Rafferty et al. | Sep 2013 | A1 |
20130274565 | Langer et al. | Oct 2013 | A1 |
20130317852 | Worrell et al. | Nov 2013 | A1 |
20130325078 | Whiting et al. | Dec 2013 | A1 |
20140025131 | Sullivan et al. | Jan 2014 | A1 |
20140025132 | Libbus et al. | Jan 2014 | A1 |
20140070957 | Longinotti-Buitoni et al. | Mar 2014 | A1 |
20140081162 | Snell et al. | Mar 2014 | A1 |
20140150781 | Capua et al. | Jun 2014 | A1 |
20140163395 | Sapp, Jr. et al. | Jun 2014 | A1 |
20140163663 | Poddar et al. | Jun 2014 | A1 |
20140324112 | Macho et al. | Oct 2014 | A1 |
20140378812 | Saroka et al. | Dec 2014 | A1 |
20150037636 | Amsler et al. | Feb 2015 | A1 |
20150039053 | Kaib et al. | Feb 2015 | A1 |
20150105835 | Thakur | Apr 2015 | A1 |
20150265845 | Sullivan et al. | Sep 2015 | A1 |
20150297107 | Sullivan et al. | Oct 2015 | A1 |
20150328472 | Sullivan et al. | Nov 2015 | A1 |
20160000349 | Sullivan et al. | Jan 2016 | A1 |
20160004831 | Carlson et al. | Jan 2016 | A1 |
20160007877 | Felix et al. | Jan 2016 | A1 |
20160015329 | Kohlrausch et al. | Jan 2016 | A1 |
20160067514 | Sullivan | Mar 2016 | A1 |
20160074667 | Sullivan | Mar 2016 | A1 |
20160082277 | Foshee, Jr. et al. | Mar 2016 | A1 |
20160106332 | Takeshima | Apr 2016 | A1 |
20160121100 | Crone | May 2016 | A1 |
20160235320 | Sarkar et al. | Aug 2016 | A1 |
20160278698 | Freeman et al. | Sep 2016 | A1 |
20160331984 | Firoozabadi et al. | Nov 2016 | A1 |
20160353996 | Fink | Dec 2016 | A1 |
20170056682 | Kumar et al. | Mar 2017 | A1 |
20170157416 | Medema | Jun 2017 | A1 |
20170252571 | Dascoli et al. | Sep 2017 | A1 |
20180028083 | Greenhut et al. | Feb 2018 | A1 |
20180093102 | Sullivan et al. | Apr 2018 | A1 |
20180116537 | Sullivan et al. | May 2018 | A1 |
20180117299 | Gustavson et al. | May 2018 | A1 |
20180184933 | Sullivan et al. | Jul 2018 | A1 |
20180185662 | Foshee, Jr. et al. | Jul 2018 | A1 |
20180221648 | Gustavson et al. | Aug 2018 | A1 |
20180264279 | Kim et al. | Sep 2018 | A1 |
20180318593 | Sullivan | Nov 2018 | A1 |
20190030351 | Sullivan et al. | Jan 2019 | A1 |
20190030352 | Sullivan et al. | Jan 2019 | A1 |
20200164217 | Sullivan | May 2020 | A1 |
20220032077 | Sullivan et al. | Feb 2022 | A1 |
Number | Date | Country |
---|---|---|
2942933 | Aug 2015 | CA |
103405851 | Nov 2013 | CN |
9839061 | Sep 1998 | WO |
Entry |
---|
U.S. Appl. No. 15/880,853, filed Jan. 26, 2018, Joseph L. Sullivan, Entire Document. |
U.S. Appl. No. 16/268,870, filed Feb. 6, 2019, Joseph L. Sullivan, Entire Document. |
U.S. Appl. No. 16/360,984, filed Mar. 21, 2019, Joseph L. Sullivan, Entire Document. |
U.S. Appl. No. 16/366,313, filed Mar. 27, 2019, Joseph L. Sullivan, Entire Document. |
U.S. Appl. No. 16/554,410, filed Aug. 28, 2019, Joseph L. Sullivan, Entire Document. |
U.S. Appl. No. 62/630,398, filed Feb. 14, 2018, Sullivan, Entire Document. |
Duncker et al. “Real-world Experience of 355 Consecutive Patients with a Wearable Cardioverter/Debrillator—Single Centre Analysis” Europace 2017, No. 19 Supplemental 3, iii304. |
EPO Search Report dated Dec. 19, 2018 on EP Application No. 1816221.0-1224. |
EPO Search report dated Sep. 27, 2018 on EP Application 18186229.3-1224. |
European Search Report of European Application 16202067.1-1666, dated Apr. 25, 2017. |
First Office action and Search Report dated Aug. 30, 2018, to CN Patent Application No. 2016111063501. |
Heartstart MRx and XL AED Algorithm—Application Note, Jul. 2001, Edition 2 Philips Healthcare, USA. |
Klein, H. U., Goldenberg I., & Moss, A. J., Risk Stratification for Implantable Cardioverter Defibrillator Therapy: The Role of the Wearable Cardioverter-Defibrillator, Clinical update, European Heart Journal, May 31, 2013, pp. 1-14, doi:10.1093/eurheartj/eht167, European Society of Cardiology. |
LIFECOR LifeVest System Model WCD 3100 Operator's Manual, 2006, PN 20B0040 Rev FI, Zoll Lifecor Corporation, Pittsburgh, PA. |
LifeVest Model 4000 Patient Manual, Zoll, 2009, PN 20B0047 Rev B. |
Olgin JE, Pletcher MJ, Vittinghoff E, et al., “Wearable Cardioverter-Defibrillator after Myocardial Infarction,” N Engl J Med Sep. 27, 2018; 379(13):1205-1215. |
Pagan-Carlo, et al., “Encircling Overlapping Multipulse Shock Waveforms for Transthoracic Defibrillation,” JACC Journals, Dec. 1998, vol. 32 Issue 7, p. 2065-2071. |
Schuhmann et al., “Experience with the wearable cardioverter defibrillator (WCD) in high risk cardiac patients from a German single center cohort”, Heart Rhythm 2016;13(5):S254. |
Second Office Action dated May 18, 2020, to CN Patent Application No. 2016111106350.1. |
The LifeVest Network/Patient Data Management System, Zoll, 2015, 2000503 Rev A. |
WCD Performance for Clinical Review, Sullivan et al., “A Novel Wearable Cardioverter Defibrillator With Reduced false Alarm Rate,” AHA 2017. |
Number | Date | Country | |
---|---|---|---|
20220032077 A1 | Feb 2022 | US |
Number | Date | Country | |
---|---|---|---|
62630695 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16382575 | Apr 2019 | US |
Child | 17503065 | US |